Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Elekta Evo: Revolutionizing Bladder Cancer Treatment with AI-Powered Adaptive Radiation Therapy

NextEdge Admin

17 Dec 2024

2 min 37 sec

Diagnostisch Therapeutisches Zentrum,radiation therapy,imaging

Elekta (EKTA-B.ST) has announced that Diagnostisch Therapeutisches Zentrum Berlin (DTZ) has treated the first patient worldwide using Elekta Evo, its AI-powered adaptive CT-Linac. The patient, a 62-year-old male, is undergoing curative treatment for bladder cancer.

Elekta Evo enhances radiation therapy with two key features: Iris™ high-definition AI-enhanced imaging and Elekta ONE® | Online. Iris offers superior clarity in visualizing tumors and critical structures, while Elekta ONE enables faster dose calculation, AI-driven automation for contouring, and adaptive treatment planning, both online and offline, improving the efficiency of radiotherapy workflows.

For bladder cancer patients, radiation therapy offers a non-invasive alternative to surgery, which can significantly affect quality of life due to the need for bladder removal. This patient chose Elekta Evo to receive radiation therapy rather than undergoing surgery.

Dr. Matthias Lampe, a radiation oncologist and partner at DTZ, commented, “Iris significantly improves CBCT image quality with AI-enhanced reconstruction, providing clearer visibility of targets and organs-at-risk, like pelvic lymph nodes. This boosts treatment confidence, saves time, and enhances patient comfort. Evo also enables real-time treatment planning with online adaptive therapy.”

Elekta Evo’s advanced imaging and adaptive radiation therapy capabilities offer clinicians the flexibility to tailor treatments to each patient’s needs, adapting as necessary to optimize outcomes. It is now part of DTZ’s radiotherapy offerings, which include five state-of-the-art linear accelerators and Elekta ONE software solutions.

Gustaf Salford, Elekta’s President and CEO, expressed pride in the partnership with DTZ and emphasized the company’s commitment to advancing personalized oncology care. He also noted the expectation of more centers beginning treatments with Evo in the coming months.